RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: Estrogen receptor (ER) is the key therapeutic target in breast cancer. ERβhas recently been identified to be distinct from ERα. In contrast to ERα, the functions of ERβin breast cancer are still unclear. We sought to determine whether the expression of ERβcan be used as a predictive marker for endocrine therapy for patients with ERα-negative breast cancer. Methods: Formalin-fixed, paraffinembedded tumor specimens from 52 patients with ER-/PR+invasive breast cancer were immunostained for their ERβ expression. These patients were treated with adjuvant tamoxifen. The results were correlated with various clinicopathological variables and the follow-up data. The expressions of p53 and HER-2/neu were also analyzed and correlated with the ERβstatus. Results: An ERβexpression was observed in 53.8% (28/52) of the breast cancer samples. There was no correlation between the ERβexpression and the other clinicopathologic factors (age, tumor size, histologic type, nodal status, histological grade, stage, therapeutic modality, progesterone receptor (PR) expression, p53 expression and HER-2/neu expression). Recurrence was present in 7.7% (2/26) of the patients whose tumors had an ERβexpression, as compared to the presence of recurrence in 36.4% (8/22) of the patients whose tumors had no ERβexpression (p<0.05). The patients with ERβnegative-tumors revealed lower disease free survival rate than those with ERβpositive-tumors (p<0.05). Of the 52 patients, 10(19.2%) were p53 positive, and 11 (21.2%) were HER-2/neu positive. No significant correlations were observed between ERβand p53 or HER-2/neu. Conclusion: These results suggest that ERβmight be a predictive marker of a response to endocrine therapy in patients with ER-/PR+ invasive breast cancer, although this needs to be confirmed by additional studies.

참고문헌 (Reference)

1 Nakopoulou L, "The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer" 57 : 523-528, 2004

2 Osborne CK, "Tamoxifen in the treatment of breast cancer" 339 : 1609-1618, 1998

3 Early Breast Cancer Trialists'Collaborative Group, "Tamoxifen for early breast cancer: an overview of the randomised trials" 351 : 1451-1467, 1998

4 Early Breast Cancer Trialists'Collaborative Group, "Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women" 339 : 1-15, 1992

5 Greene GL, "Sequence and expression of human estrogen receptor complementary DNA" 231 : 1150-1154, 1986

6 Association of Directors of Anatomic and Surgical Pathology, "Recommendations for the reporting of breast carcinoma" 27 : 220-224, 1996

7 Borgquist S, "Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer" 61 : 197-203, 2008

8 Hopp TA, "Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer" 10 : 7490-7499, 2004

9 Myers E, "Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer" 91 : 1687-1693, 2004

10 Hu YF, "Increased expression of estrogen receptor beta in chemically transformed human breast epithelial cells" 12 : 1225-1228, 1998